Recognized Standards, Recognition List Number: 039'' will be available *http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Standards/ucm123792.htm.*

You may access ''Guidance on the Recognition and Use of Consensus Standards,'' and the searchable database for ''FDA Recognized Consensus Standards'' at *http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Standards.*

VI. Submission of Comments and Effective Date

Interested persons may submit either electronic comments regarding this document to *http://www.regulations.gov* or written comments to the Division of Dockets Management (see **ADDRESSES**). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at *http://www.regulations.gov.* FDA will consider any comments received in determining whether to amend the current listing of modifications to the list of recognized standards, Recognition List Number: 039. These modifications to the list of recognized standards are effective upon publication of this notice in the **Federal Register**.

Dated: February 5, 2015.

Leslie Kux,

Associate Commissioner for Policy.

[FR Doc. 2015–02801 Filed 2–10–15; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; 60-Day Comment Request; Population Assessment of Tobacco and Health (PATH) Study

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) The quality, utility, and clarity of the information to be collected; and (4) The approaches used to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

To Submit Comments and for Further Information: To obtain a copy of the data collection plans and instruments, submit comments in writing or request more information on the proposed project, contact: Kevin P. Conway, Ph.D., Deputy Director, Division of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 5185; or call non-toll-free number (301)–443–8755; or Email your request, including your address to: *PATHprojectofficer@mail.nih.gov.* Formal requests for additional plans and instruments must be requested in writing.

Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Proposed Collection: Population Assessment of Tobacco and Health (PATH) Study—Third Wave of Data Collection—0925–0664–REVISION—National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), in partnership with the Food and Drug Administration (FDA).

Need and Use of Information Collection: This is a revision request (OMB 0925–0664, Exp. Date 9/30/2016) for the Population Assessment of Tobacco and Health (PATH) Study to conduct the third wave of data collection. The PATH Study is a large national longitudinal cohort study on tobacco use behavior and health among the U.S. household population of adults age 18 and older and youth ages 12 to 17. The PATH Study conducts annual interviews and collects biospecimens from adults to help inform the development, implementation, and evaluation of tobacco-product regulations by FDA in meeting its mission under the Family Smoking Prevention and Tobacco Control Act (TCA) to regulate tobacco products, including tobacco-product advertising, labeling, marketing, constituents, ingredients, and additives. The longitudinal design of the PATH Study provides it with the capacity to measure and report within-person changes and between-person differences in tobacco product use behaviors and health effects within the cohort over time. These data will help to inform regulatory decisions and actions by FDA and FDA's evaluations of associations between its regulations and tobacco use behaviors and health indicators in the population.

OMB approval is requested for 3 years. There are no capital, operating, or maintenance costs to report. There are no costs to respondents other than their time. The total estimated annualized burden hours are 53,459.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent and instrument	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Adults—Adult respondents at Wave 1 or Wave 2—Extended Interview	25,692	1	1	25,692
Adults—Wave 1 youth respondents who age up to adult cohort at Wave 3—Consent for Extended Interview	2,317	1	4/60	154
Adults—Wave 1 youth respondents who age up to adult cohort at Wave 3—Extended Interview	1,738	1	68/60	1,970
Adults—Wave 1 youth respondents who age up to adult cohort at Wave 3—Consent for Biological Samples	1,738	1	5/60	145
Adults—Biospecimen Collection: Urine	13,703	1	10/60	2,284

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Type of respondent and instrument	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Adults—Biospecimen Collection: Blood	869	1	18/60	261
Adults—Tobacco Use Form	14,572	1	4/60	971
Adults—Follow-up/Tracking Participant Information Form	27,430	2	8/60	7,315
Youth—Youth respondents at Wave 1 or Wave 2—Extended Interview	9,515	1	32/60	5,075
Youth—Shadow youth who age up to youth cohort at Wave 3—Assent for Extended Interview	2,420	1	3/60	121
Youth—Shadow youth who age up to youth cohort at Wave 3—Extended Interview	1,912	1	42/60	1,338
Adult—Youth respondents at Wave 1 or Wave 2—Parent Interview	9,705	1	14/60	2,265
Adults—Parents of Shadow youth who age up to youth cohort at Wave 3—Parent Permission and Consent for Parent Interview	2,420	1	5/60	202
Adults—Parents of Shadow youth who age up to youth cohort at Wave 3—Parent Interview	1,950	1	17/60	553
Adults—Verification Interview	35,564	1	2/60	1,185
Adults—Validation Interview	3,613	1	4/60	241
Adults—Follow-up/Tracking Participant Information Form for Youth (completed by parents)	11,427	2	8/60	3,047
Adults—Follow-up/Tracking Participant Information Form for sample Shadow youth (completed by parents)	2,401	2	8/60	640

Dated: February 5, 2015.

Genevieve deAlmeida-Morris,

Project Clearance Liaison, National Institute on Drug Abuse, NIH.

[FR Doc. 2015–02832 Filed 2–10–15; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; NIAMS Clinical Study Applications.

Date: March 20, 2015.

Time: 8:00 a.m. to 3:30 p.m.

Agenda: To review and evaluate grant applications

Place: National Institutes of Health, One Democracy Plaza, Suite 800, 6701 Democracy Boulevard, Bethesda, MD 20892.

Contact Person: Kan Ma, Ph.D., Scientific Review Officer, Scientific Review Branch National Institute of Arthritis, Musculoskeletal and Skin Diseases, NIH, 6701 Democracy Boulevard, Suite 814, Bethesda, MD 20892, 301–451–4838 *mak2@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: February 5, 2015.

Carolyn Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–02758 Filed 2–10–15; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Neurological Disorders and Stroke Special Emphasis Panel, March 16, 2015, 08:00 a.m. to March 17, 2015, 06:00 p.m., Bethesda North Marriott Hotel & Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852 which was published in the **Federal Register** on January 23, 2015, 80FRN3613.

The meeting has been changed to a teleconference meeting. The date and time remain the same. The meeting is closed to the public.

Dated: February 5, 2015.

Carolyn Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–02757 Filed 2–10–15; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Microbiology, Infectious Diseases and AIDS Initial Review Group; Microbiology and Infectious Diseases B Subcommittee.